176 related articles for article (PubMed ID: 18183485)
21. Antitumor effect of the antiestrogen, tamoxifen, ona pregnancy-dependent mouse mammary tumor (TPDMT-4).
Matsuzawa A; Mizuno Y; Yamamoto T
Cancer Res; 1981 Jan; 41(1):316-24. PubMed ID: 7448771
[TBL] [Abstract][Full Text] [Related]
22. Progression of pregnancy-dependent mouse mammary tumors after long dormancy periods. Involvement of Wnt pathway activation.
Gattelli A; Cirio MC; Quaglino A; Schere-Levy C; Martinez N; Binaghi M; Meiss RP; Castilla LH; Kordon EC
Cancer Res; 2004 Aug; 64(15):5193-9. PubMed ID: 15289324
[TBL] [Abstract][Full Text] [Related]
23. Steroid hormone receptors in mammary carcinoma: the effect of tamoxifen.
Koenders AJ; Beex LV; Geurts-Moespot J; Benraad TJ
Eur J Cancer (1965); 1980; Suppl 1():63-6. PubMed ID: 7318871
[No Abstract] [Full Text] [Related]
24. Polyamines and hormonal regulation of N-nitrosomethylurea-induced rat mammary tumor growth in vivo.
Manni A; Wright C; Demers L; Luk G
Cancer Res; 1986 Oct; 46(10):4938-41. PubMed ID: 3756855
[TBL] [Abstract][Full Text] [Related]
25. Protective effects of progesterone and tamoxifen in estrogen-induced mammary carcinogenesis in ovariectomized W/Fu rats.
Inoh A; Kamiya K; Fujii Y; Yokoro K
Jpn J Cancer Res; 1985 Aug; 76(8):699-704. PubMed ID: 3930447
[TBL] [Abstract][Full Text] [Related]
26. Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression.
Vanzulli SI; Soldati R; Meiss R; Colombo L; Molinolo AA; Lanari C
Carcinogenesis; 2005 Jun; 26(6):1055-63. PubMed ID: 15774491
[TBL] [Abstract][Full Text] [Related]
27. Reversal of antiprogestin resistance and progesterone receptor isoform ratio in acquired resistant mammary carcinomas.
Wargon V; Helguero LA; Bolado J; Rojas P; Novaro V; Molinolo A; Lanari C
Breast Cancer Res Treat; 2009 Aug; 116(3):449-60. PubMed ID: 18677559
[TBL] [Abstract][Full Text] [Related]
28. Effect of progesterone on cell proliferation in the MXT mouse hormone-sensitive mammary neoplasm.
Kiss R; Paridaens RJ; Heuson JC; Danguy AJ
J Natl Cancer Inst; 1986 Jul; 77(1):173-8. PubMed ID: 3459912
[TBL] [Abstract][Full Text] [Related]
29. Estradiol and progersterone receptors in F1 (C3H X RIII) mice mammary tumors: effect of castration.
Edery M; Drosdowsky MA
Biomedicine; 1980 May; 33(3):80-2. PubMed ID: 7448327
[TBL] [Abstract][Full Text] [Related]
30. Novel human breast cancer cell lines IBH-4, IBH-6, and IBH-7 growing in nude mice.
Bruzzone A; Vanzulli SI; Soldati R; Giulianelli S; Lanari C; Lüthy IA
J Cell Physiol; 2009 May; 219(2):477-84. PubMed ID: 19194992
[TBL] [Abstract][Full Text] [Related]
31. Morphology of human uterine cancer in nude mice. Effects of hormone and antihormone treatment.
Zaino RJ; Satyaswaroop PG; Mortel R
Arch Pathol Lab Med; 1984 Jul; 108(7):571-8. PubMed ID: 6547322
[TBL] [Abstract][Full Text] [Related]
32. Accelerated progression to autonomy of a pregnancy-dependent mouse mammary tumor (TPDMT-4) by hormones.
Matsuzawa A; Kaneko T; Ikeda Y
Cancer Res; 1983 May; 43(5):2283-9. PubMed ID: 6831452
[TBL] [Abstract][Full Text] [Related]
33. The role of GABA-ergic system in human mammary gland pathology and in growth of transplantable murine mammary cancer.
Opolski A; Mazurkiewicz M; Wietrzyk J; Kleinrok Z; Radzikowski C
J Exp Clin Cancer Res; 2000 Sep; 19(3):383-90. PubMed ID: 11144533
[TBL] [Abstract][Full Text] [Related]
34. Reversal of estrogen-resistance in murine mammary adenocarcinomas.
Montecchia MF; Molinolo A; Lanari C
Breast Cancer Res Treat; 1999 Mar; 54(2):93-9. PubMed ID: 10424399
[TBL] [Abstract][Full Text] [Related]
35. [Estradiol reception and enzyme induction in mouse mammary gland neoplasms].
Merkulova TI; Morozova TM; Iakovleva GE; Salganik RI
Vopr Onkol; 1978; 24(8):19-26. PubMed ID: 695420
[TBL] [Abstract][Full Text] [Related]
36. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma.
Hammoud Z; Tan B; Badve S; Bigsby RM
Endocr Relat Cancer; 2008 Jun; 15(2):475-83. PubMed ID: 18509000
[TBL] [Abstract][Full Text] [Related]
37. [Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer].
Abe R; Sawano A; Ueki H; Akimoto M; Kimura M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):785-92. PubMed ID: 3566291
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic change of the transplantable MXT mammary adenocarcinoma into mixed bone producing sarcoma-like tumors.
Kiss R; Devleeschouwer N; Paridaens RJ; Danguy A; Heuson JC; Atassi G
Anticancer Res; 1986; 6(4):753-9. PubMed ID: 3463244
[TBL] [Abstract][Full Text] [Related]
39. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
[TBL] [Abstract][Full Text] [Related]
40. [Important "reference conditions" in the interpretation of hormone receptor findings in human breast carcinomas. Studies of the nude mouse model].
Michel RT; Bastert G
Med Welt; 1983 Mar; 34(12):373-7. PubMed ID: 6855536
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
